FC25: Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis: An Online Activity

In this 45-minute symposium, expert faculty cover the latest updates for JAK inhibitors, including head-to-head efficacy and safety data for JAK inhibitors and biologics, and share clinical pearls for using JAK inhibitors in dermatology practice for atopic dermatitis.

"I can say that in my clinic, I am reaching for those high bars. You have toput yourself in the position of the patient or imagine that patient is your family member. Would you want mediocre treatment for them or average treatment or moderate treatment? You’d want them to get the best possible treatment. In my practice I’m now counseling patients 'yes we want clear skin. Yes, we want minimal itch. Yes we want your skin pain gone and for you to sleep better.'”- David Cotter, MD, PhD

FC25: Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis: An Online Activity

This activity is supported by an educational grant from AbbVie.